0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)]

Biogen Inc. (BIIB)  More Company Research Source: Reuters
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Coronavirus delays Biogen's Spinraza for some patients - Reuters 1 Min Read NEW YORK (Reuters) - U.S. drugmaker Biogen Inc said on Wednesday that some patients on its drug Spinraza - which treats a rare disorder called spinal muscular atrophy (SMA) - are having their treatments postponed to prioritize COVID-19 patients. SMA is the leading genetic cause of death in infants. Biogen did not give further details about how many patients were having their treatment delayed by the fast-moving outbreak, where they are located or how long the delays are. The company said it would work with health systems and institutions to provide access to the critical therapy for people with SMA. Patients group Cure SMA said in a statement released earlier on Wednesday that receiving the drug on time is a high priority for SMA patients but that a “few weeks delay should not have a huge impact.” Reporting by Michael Erman; Editing by Stephen Coates All quotes delayed a minimum of 15 minutes. See here for a [Read more]
IMPACT SNAPSHOT EVENT TIME: BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BIIB alerts
from News Quantified
BIIB
NEWS
BIIB
Earnings
BIIB
Analyst Actions
BIIB
SEC Filings
Stockreport

Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)]

Biogen Inc.  (BIIB) 
More Company Research Source: Reuters
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Coronavirus delays Biogen's Spinraza for some patients - Reuters 1 Min Read NEW YORK (Reuters) - U.S. drugmaker Biogen Inc said on Wednesday that some patients on its drug Spinraza - which treats a rare disorder called spinal muscular atrophy (SMA) - are having their treatments postponed to prioritize COVID-19 patients. SMA is the leading genetic cause of death in infants. Biogen did not give further details about how many patients were having their treatment delayed by the fast-moving outbreak, where they are located or how long the delays are. The company said it would work with health systems and institutions to provide access to the critical therapy for people with SMA. Patients group Cure SMA said in a statement released earlier on Wednesday that receiving the drug on time is a high priority for SMA patients but that a “few weeks delay should not have a huge impact.” Reporting by Michael Erman; Editing by Stephen Coates All quotes delayed a minimum of 15 minutes. See here for a [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BIIB
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS